First Allied Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

First Allied Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$214K	Buy	+2,561	New	+$227K	0.01%	1041
2018 Q4	–	Sell	-8,105	Closed	-$355K	–	1087
2018 Q3	$355K	Sell	8,105 -16,135	-67%	-$845K	0.01%	836
2018 Q2	$1.43M	Sell	24,240 -34,665	-59%	-$1.97M	0.05%	359
2018 Q1	$2.69M	Buy	+58,905	New	+$2.43M	0.1%	224

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Allied Advisory Services's CRSP Position: Q3 2020 in Review

First Allied Advisory Services opened a new position in CRISPR Therapeutics (CRSP) in Q3 2020: 2,561 shares worth $214K. The stake represents 0.01% of the portfolio and ranks #1041 among its holdings. This is a return to the name: First Allied Advisory Services previously reported a position in CRSP as recently as Q3 2018.

First Allied Advisory Services first reported a position in CRSP in Q1 2018 and has held it in 4 quarters since. The position peaked at $2.69M in Q1 2018. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

First Allied Advisory Services held 2,561 shares of CRISPR Therapeutics worth $214K as of Q3 2020.
CRISPR Therapeutics was a new First Allied Advisory Services position in Q3 2020.
CRISPR Therapeutics made up 0.01% of First Allied Advisory Services's portfolio in Q3 2020, its #1041 holding.
First Allied Advisory Services first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 4 quarters since.
First Allied Advisory Services's CRISPR Therapeutics position peaked at $2.69M in Q1 2018.
310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.